Target
Delta-like ligand 3 (DLL3)
3 abstracts
Abstract
Tumor microenvironment-mediated immune profiles and efficacy of platinum doublet chemotherapy plus ICIs stratified by DLL3 expression in small cell lung cancer.Org: National Cancer Center Hospital East, Kashiwa, Japan, Division of Genome Biology, National Cancer Center Research Institute, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Respiratory Medicine, NHO Iwakuni Clinical Center, Iwakuni, Japan,
Abstract
Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304).Org: Hospital Universitario 12 de Octubre, CNIO-H120 Lung Cancer Unit, Ciberonc and Universidad Complutense, Madrid, Spain, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South), The Christie NHS Foundation Trust, Division of Cancer Sciences, Manchester, United Kingdom, Fox Chase Cancer Center, Philadelphia, PA,
Abstract
Prevalence of delta-like ligand 3 expression in small cell lung cancer.Org: EpidStrategies, a division of ToxStrategies, LLC, Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands, Amgen,